Frankfurt - Delayed Quote EUR

Grifols, S.A. (G0F.F)

3.9800

0.0000

(0.00%)

As of 8:09 AM GMT+2. Market Open.

Grifols 2023 Annual Report on Form 20-F filed with the SEC

Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the United States Securities and Exchange Commission ("SEC").

PR Newswire 3 days ago
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.

The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a top-three plasma industry leader and setting the stage for sustained business growth The flagship Grifols campus is a touchstone of Grifols’ leadership in plasma therapeutics, producing about 40% of the company’s total medicinal output globally and helping enhance the quality of life of patients all over the worldAn engineering masterwork, the Clayton site is a model for new Grifols plants whi

GlobeNewswire 4 days ago
Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

Grifols’ in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of transfusion-transmitted infections Arboviruses are a growing emerging threat, with changes in climate and increasing global connectivity making the geographic spread more prevalent CE mark for Grifols’ Procleix ArboPlex Assay reinforces the company’s leadership in transfusion medicine and commitment to ensuring the safety of the world’s blood supply BARCELONA, Spain, April 04, 2024 (GLOBE NEWSWIRE

GlobeNewswire 19 days ago
Grifols announces positive topline phase 3 fibrinogen clinical trial results

In the AdFIrst study, Biotest's fibrinogen concentrate (FC), BT524, met the primary endpoint, demonstrating its effectiveness in treating acquired fibrinogen deficiency (AFD) as equivalent to standard of care, while maintaining an excellent safety profileRegulatory approval process in Europe and United States set to begin in Q4 2024. It would be the first FC approved for an AFD indication in the U.S. in a global market for AFD with an estimated potential of USD 800 millionThis milestone is part

GlobeNewswire 2 months ago
Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients

Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines and innovative diagnostic solutions, today announced the launch of its new Grifols sCD38 solution, the industry's first-ever soluble recombinant protein designed to block anti-CD38 antibodies in multiple myeloma patients receiving daratumumab therapy, ensuring quick and accurate blood transfusion tests that are critical for proper treatment.

PR Newswire 5 months ago
Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Study designed to demonstrate impact of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%), an alpha1 antitrypsin treatment, compared with Liquid Alpha1-Proteinase Inhibitor (Human) intravenousThis first in-human subcutaneous approach to treating alpha1-antitrypsin deficiency, if proven successful in clinical trials, could give patients the convenience and flexibility to administer their medication from home BARCELONA, Spain, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, M

GlobeNewswire 5 months ago
GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023

Researchers from the National Cancer Institute will conduct the Phase 1 trial, as established in a recently signed Cooperative Research and Development Agreement (CRADA) GigaGen anticipates trial initiation in 2024 GIGA-564 is a differentiated anti-CTLA-4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities associated with traditional CTLA-4 blockade SAN CARLOS, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing tran

GlobeNewswire 5 months ago
Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD

Trial met primary endpoints, confirming vaccine’s safety, tolerability and robust immune response against the Aβ40 peptide in early-stage Alzheimer's patientsABvac40 treatment slowed disease progression up to 38% compared with placebo as measured by the Mini-Mental State Examination scoreVaccine’s unique design offers a new approach to address growing need for effective Alzheimer’s treatments as the prevalence of Alzheimer’s disease is expected to double by the year 2050 in the U.S. alone1 ZARAG

GlobeNewswire 5 months ago
GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum Neurotoxins

Modified agreement expands total grant value to $11.8M to advance development activities including manufacturing and investigational new drug (IND)-enabling studiesSOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the company has been granted an expansion of its contract with the U.S.

GlobeNewswire 6 months ago
GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564

Collaboration sets stage for GigaGen’s first oncology asset to enter clinical development GIGA-564 is a differentiated anti-CTLA4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities associated with traditional CTLA-4 blockade GigaGen and NCI will present investigational new drug (IND)-enabling data and clinical trial strategy for GIGA-564 at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting SAN CARLOS, Calif., Sept. 28, 2023 (GLOBE NEWSW

GlobeNewswire 6 months ago
Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and Analytics

Grifols will apply artificial intelligence technologies, including large language models, to speed up the development of new biopharma therapeuticsAgreement is latest Grifols initiative to reinforce the robustness of its therapeutic pipeline and strengthen its innovation culture BARCELONA, Spain, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people’s health and

GlobeNewswire 8 months ago
Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients

Clinical trial met primary endpoint demonstrating comparable total immunoglobulin (Ig) levels when administering XEMBIFY® (Grifols’ subcutaneous Ig) every two weeks, compared with weekly, in patients with primary immunodeficienciesStudy designed to support extending U.S. Food and Drug Administration labeling of XEMBIFY® to include biweekly dosing, providing added flexibility and convenience for patientsGrifols is accelerating adoption of XEMBIFY® as part of its broader immunoglobulin business st

GlobeNewswire 8 months ago
Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

PRECIOSA clinical trial is designed to evaluate efficacy and safety of Grifols Albutein® plus standard medical treatment to increase survival time in patients with decompensated cirrhosis awaiting transplantAlbumin’s antioxidant and anti-inflammatory properties have the potential to mitigate the complications associated with decompensated cirrhosisGrifols continues innovating across its plasma-protein franchise and is committed to applying its ever-growing expertise in a range of therapeutic are

GlobeNewswire 9 months ago
Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin®-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Target of 339 patients enrolled has been met in the SPARTA clinical trial, designed to evaluate efficacy and safety of two separate weekly doses of Grifols’ Prolastin®-C (Alpha1-Proteinase Inhibitor [Human]) to slow emphysema progression in patients with alpha-1-antitrypsin (AAT) deficiency (known as alpha-1)Alpha-1 is the most common genetic risk factor for chronic obstructive pulmonary disease (COPD), a group of respiratory diseases that includes emphysema. COPD is the third leading cause of d

GlobeNewswire 9 months ago
Grifols Launches AlphaID™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPD

Now available in the U.S., this free, innovative genetic health risk service lets consumers screen for their risk of alpha1-antitrypsin deficiency (alpha-1) through a small saliva sample they can collect right at home without needing to visit a healthcare professionalAlpha-1 is the most common genetic risk factor for chronic obstructive pulmonary disease (COPD), a group of respiratory diseases affecting around 16 million Americans and the fourth-leading cause of death in the U.S.1As the leader i

GlobeNewswire 11 months ago

Performance Overview

Return	G0F.F	IBEX 35...
YTD	-46.22%	+8.82%
1-Year	-10.36%	+16.76%
3-Year	--	+26.45%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Grifols, S.A. (G0F.F)

Grifols 2023 Annual Report on Form 20-F filed with the SEC

Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

Grifols announces positive topline phase 3 fibrinogen clinical trial results

Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023

Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD

GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum Neurotoxins

GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564

Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and Analytics

Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin®-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Launches AlphaID™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPD

Performance Overview